Appointment of Corporate Broker

RNS Number : 2533H
Destiny Pharma PLC
23 November 2022
 

 

23 November 2022

 

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Appointment of Corporate Broker

 

Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, is pleased to announce the appointment of Shore Capital as joint corporate broker, to work alongside the Company's Nominated Adviser and existing corporate broker finnCap Ltd, with immediate effect.

 

 

For further information, please contact:

 

Destiny Pharma plc 

Neil Clark, CEO

Shaun Claydon, CFO

 

+44 (0)1273 704 440

pressoffice@destinypharma.com

finnCap Ltd (Nominated Adviser and Joint Broker) 

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

 

+44 (0) 207 220 0500

Shore Capital (Joint Broker) 

Daniel Bush / James Thomas / Lucy Bowden

 

+44 (0) 20 7408 4090

Optimum Strategic Communications

Mary Clark / Nick Bastin / Manel Mateus 

 

+44 (0) 208 078 4357

DestinyPharma@optimumcomms.com

MC Services AG

Anne Hennecke / Andreas Burckhardt

 

+49-211-529252-12

Stern IR - US

Janhavi Mohite

 

+1-212-362-1200

Janhavi.Mohite@sternir.com

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information on the company, please visit   https://www.destinypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEALFAAFLAFFA
UK 100

Latest directors dealings